Reduction Of Frown Lines

Sent to you by Vachak via Google Reader:

Mentor Corporation Announces Completion Of PurTox(R) 3A Study

via Health News from Medical News Today

Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetic market, today announced completion of the first of three Phase 3 clinical trials with its purified botulinum Type A neurotoxin (PurTox®) for the reduction of glabellar rhytides (frown lines). This newly completed study involved 400 subjects at ten investigational sites in the United States.